Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronocort in Congenital Adrenal Hyperplasia (CAH) Extension Study
NCT05299554Phase 3Completed
- Sponsor
- Immedica
- Start
- Apr 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH), sponsored by Immedica. Started Apr 2022; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT05299554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299554.